Previous 10 |
Shares of CinCor Pharma Inc. (NASDAQ:CINC) traded at a new 52-week high today of $28.75. This new high was reached on below average trading volume as 101,000 shares traded hands, while the average 30-day volume is approximately 196,000 shares. CinCor Pharma Inc is a clinical-stage biopha...
Vancouver, Kelowna, Delta, BC - February 25, 2022 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech, Cannabis and Mining. Today's stocks have been added to our lists of free sto...
Shares of CinCor Pharma Inc. (NASDAQ:CINC) traded today at $25.20, eclipsing its 52-week high. So far today approximately 101,000 shares have been exchanged, as compared to an average 30-day volume of 271,000 shares. CinCor Pharma Inc is a clinical-stage biopharmaceutical company focused...
The biotech sector is also presenting exciting opportunities for investors. Many of the best biotech companies have both strong drug candidate pipelines and winning drugs already on the market. The COVID-19 pandemic has also created massive opportunities for biotechnology companies. According...
BOSTON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced the appointment of the independent member June Lee, M.D. to the company’s Board of Directors. Dr. Lee brings decades of leadership experience in the biotechnology and pharmaceutical industry ...
News, Short Squeeze, Breakout and More Instantly...
CinCor Pharma Inc. Company Name:
CINC Stock Symbol:
NASDAQ Market:
WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor” or the “Company”) announced today completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (“FDA”) on the anticipated Phase 3 program for baxdrostat ...
Two somewhat under-the-radar biotech companies saw their share prices soar this week after agreeing to be acquired. CinCor Pharma (NASDAQ: CINC) is being bought out by deep-pocketed pharmaceutical company AstraZeneca , while Albireo Pharma (NASDAQ: ALBO) is set to be owned by ...